科兴制药 (688136.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

16.0x

Market Cap

CNY 4.77B

MomentumView details →

1D Return

+14.84%

YTD Return

—

RSI (14)

47.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

16.0x

Market Cap

CNY 4.77B

RSI (14)

47.5

MomentumView details →

1D Return

+14.84%

YTD Return

—

ProfitabilityView details →

Gross Margin

61.37%

Net Margin

7.67%

EBITDA Margin

18.63%

ROE (TTM)

6.49%

ROA (TTM)

3.21%

Asset Turnover

0.42x

GrowthView details →

Revenue YoY

+4.37%

EPS YoY

+150.25%

FCF YoY

—

Revenue CAGR 3Y

+5.25%

EPS CAGR 3Y

+393.75%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

1.50x

Quick Ratio

1.35x

Div Yield

1.23%

Div Rate

CNY 0.25

Div Growth 1Y

+212.50%

Financials snapshotView financials →

Revenue (TTM)

1.46B

Net Income (TTM)

112.05M

Op. CF (TTM)

67.50M

Latest newsMore news →

Kexing Pharmaceutical signed a commercialization cooperation agreement with Huayi Taikang Pharmaceutical to jointly promote the commercialization of metoprolol succinate extended-release tablets in the Hong Kong, China market, with Kexing responsible for registration and commercialization.9d ago

Kexing Pharmaceutical announced its first-half 2026 results: revenue of 607 million yuan, net profit of 134 million yuan, up 66.71% year-on-year.14d ago

Similar companies

康辰药业603590.SH ACADIA Pharmaceuticals Inc.ACAD Celcuity Inc.CELC Edgewise Therapeutics, Inc.EWTX 三力制药603439.SH Jacobio Pharmaceuticals Group Co., Ltd.01167.HK Find similar companies →

Latest newsMore news →

Kexing Pharmaceutical signed a commercialization cooperation agreement with Huayi Taikang Pharmaceutical to jointly promote the commercialization of metoprolol succinate extended-release tablets in the Hong Kong, China market, with Kexing responsible for registration and commercialization.9d ago Kexing Pharmaceutical announced its first-half 2026 results: revenue of 607 million yuan, net profit of 134 million yuan, up 66.71% year-on-year.14d ago